US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults
June 12 (Reuters) - The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's MRNA.O respiratory syncytial virus vaccine to a lower group of high-risk adults aged 18 to 59 years.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Meme Stocks Reappear. Avis Shares Reach New Highs Amid Short Squeeze. Can Retail Investors Still Buy?

SpaceX IPO: Musk Weighs $60 Billion Cursor Deal, and Can It Save xAI?

Intel Q1 2026 Earnings Preview: The Rally is Ahead of the Fundamentals

SK Hynix Q1 2026 Earnings Preview: Memory Chip Prices Surge, Profit Set to Double

Intel Foundry Gains ‘High-Profile’ Customer, Tesla Becomes First Major Customer for 14A Technology

Tradingkey







